TLDR:
- LabGenius secures €40.9M in Series B funding led by Amsterdam’s M Ventures to advance drug discovery platform
- EVA, LabGenius’ discovery platform, integrates AI, robotic automation, and synthetic biology to develop therapeutic antibodies
London-based LabGenius, a drug discovery company, announced that it has secured £35M (approximately €40.96M) in a Series B round of funding. The company specializes in using machine learning to discover new therapeutic antibodies. The funding round was led by Amsterdam’s M Ventures, and new investors include Octopus Ventures and LG Corp. LabGenius will use the funds to enhance its platform and advance its portfolio of multispecific antibodies towards clinical development.
LabGenius is developing next-generation therapeutic antibodies using its discovery platform EVA, which integrates technologies like AI, robotic automation, and synthetic biology. The company operates under a hybrid business model, partnering with large biotech companies while also developing its own therapeutic pipeline. EVA, the smart robotic platform, can design, conduct, and learn from experiments autonomously to identify high-performing antibodies with non-intuitive designs.
The company aims to address the challenge of on-target, off-tumor toxicity in its pipeline by using Multi-Objective Bayesian Optimization (MOBO) to co-optimize antibodies across multiple properties simultaneously. LabGenius plans to leverage its collaboration with Sanofi to broaden its platform capabilities and form strategic partnerships across various therapeutic modalities. The new funding will also support the company in advancing its machine learning-driven discovery platform and pipeline development.
